Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$41.15 USD
-0.76 (-1.81%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $41.14 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARS 41.15 -0.76(-1.81%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Other News for TARS
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result
Short Report: Grindr shorts at record highs as CFO quits before earnings
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | TARS ...
ClearBridge Small Cap Strategy Q2 2025 Commentary